Trials / Active Not Recruiting
Active Not RecruitingNCT06817356
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mazdutide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-02-06
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2025-02-10
- Last updated
- 2026-03-27
Locations
25 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06817356. Inclusion in this directory is not an endorsement.